Covered recipient · General Payments record
GAFAR AJANI ADESOJI
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$2,724.98
- Reported across 181 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $267.18 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $158.32 | 10 |
| Novo Nordisk AS | $39.08 | 2 |
| Abbott Laboratories | $23.68 | 1 |
| Merck Sharp & Dohme Corporation | $17.21 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.41 | 1 |
| PFIZER INC. | $13.48 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $23.68 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125307159 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.41 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118191571 | CMS |
| Lilly USA, LLC | $14.09 | 01/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134982822 | CMS |
| Lilly USA, LLC | $13.99 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135000244 | CMS |
| Lilly USA, LLC | $17.12 | 04/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134982824 | CMS |
| Lilly USA, LLC | $16.96 | 05/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134981650 | CMS |
| Lilly USA, LLC | $15.37 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134993484 | CMS |
| Lilly USA, LLC | $18.51 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134984420 | CMS |
| Lilly USA, LLC | $16.96 | 09/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134993486 | CMS |
| Lilly USA, LLC | $13.47 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134993334 | CMS |
| Lilly USA, LLC | $13.47 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134993336 | CMS |
| Lilly USA, LLC | $18.38 | 11/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134993482 | CMS |
| Merck Sharp & Dohme LLC | $17.21 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141889650 | CMS |
| Novo Nordisk Inc | $17.31 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096701510 | CMS |
| Novo Nordisk Inc | $21.77 | 10/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097252982 | CMS |
| PFIZER INC. | $13.48 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132134247 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.